ORBIMED ADVISORS LLC 13D and 13G filings for Avalo Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-17 6:13 pm Purchase | 2025-12-31 | 13G | Avalo Therapeutics, Inc. AVTX | ORBIMED ADVISORS LLC | 1,187,300 6.400% | 220,300 (+22.78%) | Filing |
| 2025-08-14 6:00 pm Unchanged | 2025-06-30 | 13G | Avalo Therapeutics, Inc. AVTX | ORBIMED ADVISORS LLC | 967,000 8.900% | 0 (Unchanged) | Filing |
| 2024-11-14 6:43 pm Purchase | 2024-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | ORBIMED ADVISORS LLC | 2,925,900 4.200% | 2,925,900 (New Position) | Filing |
| 2024-11-14 6:23 pm Purchase | 2024-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | ORBIMED ADVISORS LLC | 967,000 9.900% | 967,000 (New Position) | Filing |